$RCEL

Woody Joseph Fralin purchased $21K of RCEL

Woody Joseph Fralin purchased 5,200 shares of AVITA Medical, Inc. (RCEL) at $4.00 on 2026-06-09.

Original reporting
SEC EDGAR · Woody Joseph Fralin
Published Jun 11, 2026, 1:17 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 11, 2026, 1:30 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$RCEL
Neutral
medium confidence
Mentioned
$RCEL
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$RCELNeutralLow
01

Why it matters

A director’s open-market purchase is incremental information about insider sentiment, but it does not provide new clinical, regulatory, financial, or deal catalysts.

02

Market read

Traders may note the buy as a minor sentiment input, but it is unlikely to drive a sustained repricing without additional company-specific catalysts.

03

What to watch

The filing notes no pre-arranged 10b5-1 plan, but the article provides no context on motivation, timing constraints, or whether other insiders/large holders acted similarly.

Relevance 4/10Novelty 8/10Timing: Filed 2026-06-10 for a 2026-06-09 insider buy

Background

The article is an SEC EDGAR Form 4 insider transaction disclosure for AVITA Medical, Inc.

Company-level read

Ticker impact

$RCELNeutralMedium confidence
Context

SEC Form 4 shows director Woody Joseph Fralin bought 5,200 shares of AVITA Medical (RCEL) for ~$20.8K on 2026-06-09.

Expected impact

Likely minimal near-term price impact; any effect would be sentiment-driven and short-lived.

Evidence & confidence

The disclosure is a small, non-10b5-1 purchase by a director; without accompanying operational/news catalysts, it rarely changes fundamentals.

Market effects

No direct sector read-through; this is a single-company insider transaction.

None indicated.

None indicated.

Counterpoint

Insider buys can be routine liquidity/compensation-related and may not reflect a change in business outlook, especially at small dollar size.

Key entities

  • AVITA Medical, Inc.

    Subject of the Form 4 insider transaction; director Woody Joseph Fralin purchased shares.

  • Woody Joseph Fralin

    Director who reported an open-market purchase of 5,200 shares on 2026-06-09.

Related articles

$RCELHighAI 9/10

Avita Medical Shares Surge After Record Second-Quarter Performance

Avita Medical (NASDAQ:RCEL) shares rose about 21.7% in premarket after it reported record Q2 results. Revenue was $21.7M, up 18% YoY and about 8% above estimates. Adjusted loss per share narrowed to $0.25 vs $0.30 expected. Full-year 2026 revenue guidance raised to $86M-$89M and cash-flow breakeven targeted for Q4 2026. BTIG upgraded to Buy with a $7.00 target.

$RCELHighAI 9/10

Why is Avita Medical stock surging 20% today?

Avita Medical (RCEL) shares rose about 22% pre-open after the company reported Q2 revenue of $21.7M, up 18% YoY and about 8% above consensus, with adjusted loss per share of $0.25 vs $0.30 expected. The firm raised 2026 revenue guidance to $86M-$89M and reiterated cash-flow breakeven in Q4 2026. BTIG upgraded RCEL to Buy and set a $7 target.

$RCELHigh

AVITA Medical, Inc. (RCEL): Results of Operations and Financial Condition

AVITA Medical, Inc. (RCEL) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 rcel-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 AVITA Medical Reports Second Quarter Results, Raises 2026 Revenue Guidance, and Expects Fourth Quarter Cash Flow Breakeven VALENCIA, Calif., August 6, 2026 (GLOBE NEWSWIRE) — AVITA Medical ® , Inc. (NASDAQ: RCEL, ASX: AVH), a